Recombinant Mouse Thrombomodulin (Thbd)

What is the molecular structure of mouse Thrombomodulin?

Mouse Thrombomodulin is a type I membrane protein encoded by the THBD gene. The protein consists of a signal peptide (amino acids 1-16) and a mature chain (amino acids 17-577). The mature chain is composed of several distinct domains: a C-type lectin domain, an EGF-like domain, a transmembrane domain, and a cytoplasmic domain. Recombinant forms typically correspond to the extracellular portion of the protein. The molecular mass of the core protein is approximately 54.6 kDa, while the apparent molecular mass is 85-90 kDa due to post-translational modifications, particularly glycosylation .

What are the primary biological functions of Thrombomodulin?

Thrombomodulin functions primarily as a high-affinity receptor for thrombin and serves as an essential cofactor in the protein C activation pathway. When thrombin binds to Thbd, the complex efficiently converts the plasma zymogen protein C into activated protein C (aPC). Additionally, the Thbd/thrombin complex activates thrombin activatable fibrinolysis inhibitor (TAFI). Through these mechanisms, Thbd plays crucial roles in regulating coagulation, fibrinolysis, inflammation, and cytoprotection. The protein C pathway activated by Thbd has significant anti-inflammatory and cytoprotective effects on various cell types, including endothelial cells, neurons, and innate immune cells .

How does mouse Thrombomodulin differ from human Thrombomodulin?

While both mouse and human Thrombomodulin share fundamental structural and functional similarities, including the domain organization and primary function as a thrombin receptor, there are species-specific differences in amino acid sequence and glycosylation patterns. These differences can affect binding affinities for thrombin and other interaction partners, as well as the efficiency of protein C activation. When designing cross-species experiments, researchers should consider these differences, as they may impact the translation of findings from mouse models to human applications .

What is the expression pattern of Thrombomodulin in mouse tissues?

Thrombomodulin is predominantly expressed in endothelial cells of small blood vessels throughout the body, though expression levels vary in different vascular beds, with lower levels observed in certain brain microvascular beds. Within the hematopoietic system, Thbd is expressed in a subpopulation of dendritic cells, monocytes, and a small subset of neutrophils. In the bone marrow, Thbd expression has been detected in various cell populations, including hematopoietic progenitor cells (HPCs), enhanced HPCs (Lin−, c-Kit+, Sca-1+ cells), CD45−Ter111−CD31+ endothelial cells, and CD45−Ter111−CD31− stromal cells. Notably, abundant Thbd expression is found within the endosteal region of the femur and in femoral blood vessel endothelial cells supplying the bone marrow .

How can Thrombomodulin expression be detected in experimental settings?

Multiple approaches can be used to detect Thrombomodulin expression in experimental settings:

• Immunohistochemistry/immunofluorescence with anti-Thbd antibodies to visualize protein expression in tissue sections

• Western blot analysis for protein detection in tissue or cell lysates

• RT-PCR or qPCR for mRNA expression analysis

• Flow cytometry for cell surface expression on specific cell populations

• Reporter systems, such as the Thbd knock-in mice expressing β-galactosidase under the control of the Thbd promoter, which allows for in situ visualization of Thbd expression

The choice of method depends on the specific research question and the level of resolution required. For instance, in situ approaches like immunohistochemistry or reporter systems provide spatial information about expression patterns, while flow cytometry allows for quantitative analysis of expression on specific cell populations .

What role does Thrombomodulin play in radiation injury and mitigation?

Thrombomodulin and the protein C pathway have been identified as critical mediators in mitigating radiation-induced tissue damage and mortality. Therapeutic administration of recombinant soluble Thbd or activated protein C (aPC) to lethally irradiated mice accelerates the recovery of hematopoietic progenitor activity in bone marrow and significantly improves survival rates. Even when aPC administration is delayed until 24 hours post-irradiation, it still provides substantial protection against radiation-induced mortality.

How does Thrombomodulin contribute to stroke outcomes and cerebrovascular function?

Thrombomodulin plays a crucial role in the ischemic brain and controls post-stroke microvascular remodeling. Endogenous Thbd expressed in brain endothelial cells promotes angiogenesis in the ischemic brain tissue. Studies using inducible brain endothelial-specific Thbd knockout mice have demonstrated that the absence of Thbd in brain endothelial cells results in larger infarcts and more severe neurological deficits following stroke. This effect is not related to altered fibrin deposition, platelet aggregation, brain edema, blood-brain barrier permeability, or inflammatory responses.

Instead, Thbd appears to control endothelial nitric oxide formation and angiogenesis in the ischemic brain through direct effects on vascular endothelium. In the absence of endothelial Thbd, the diameter of microvessels, the density of proliferating endothelial cells, and microvascular length are all reduced in the peri-infarct area. These findings establish Thbd as a master switch controlling post-stroke microvascular remodeling and tissue survival .

What is known about the role of Thrombomodulin in cancer biology?

Thrombomodulin has been implicated in various aspects of cancer biology, including tumor growth, metastasis, and angiogenesis. The expression of Thbd is often dysregulated in cancer cells, with some tumors showing increased expression while others exhibit decreased expression compared to their normal tissue counterparts. These alterations in Thbd expression can influence tumor progression through multiple mechanisms.

The protein C pathway activated by Thbd may modulate the tumor microenvironment by affecting inflammation, coagulation, and cell survival. Additionally, Thbd can directly interact with various cell surface receptors and signaling pathways that regulate cell proliferation, migration, and invasion. Understanding the complex and sometimes opposing roles of Thbd in different cancer types is an active area of research with potential implications for cancer diagnosis, prognosis, and therapeutic development .

How can recombinant mouse Thrombomodulin be used to study radiation mitigation strategies?

Recombinant mouse Thrombomodulin can be used as a valuable tool to investigate radiation mitigation strategies in several experimental approaches:

• Dose-response studies: Administering varying doses of recombinant Thbd to irradiated mice to determine optimal dosing for radioprotection.

• Timing studies: Evaluating the therapeutic window by administering Thbd at different time points before or after radiation exposure.

• Mechanistic investigations: Using Thbd in combination with inhibitors of specific signaling pathways to elucidate the molecular mechanisms underlying its radioprotective effects.

• Combination therapies: Testing Thbd in combination with other radioprotective agents to identify synergistic effects.

• Tissue-specific studies: Examining the effects of Thbd on different radiation-sensitive tissues, such as bone marrow, gastrointestinal tract, and skin.

In these applications, researchers typically administer recombinant soluble Thbd intravenously to mice before or after total body irradiation, followed by assessment of survival, hematopoietic recovery, tissue damage, and molecular markers of radiation response. The oxidation-resistant form of soluble recombinant Thbd (solulin, INN sothrombomodulin alpha) has shown significant radioprotection when administered up to 30 minutes post-irradiation, with 40-80% survival benefit compared to vehicle-treated controls .

What experimental approaches can be used to study the role of Thrombomodulin in hematopoietic stem cell biology?

Several experimental approaches can be employed to investigate Thbd's role in hematopoietic stem cell biology:

• Genetic manipulation of Thbd expression:

  • Lentiviral overexpression of Thbd in hematopoietic stem and progenitor cells (HSPCs)

  • CRISPR/Cas9-mediated knockout or knockdown of Thbd in HSPCs

  • Use of Thbd-deficient mouse models (e.g., Thbd Pro/LacZ mice)

• Competitive transplantation assays:

  • Transplanting Thbd-overexpressing or Thbd-deficient HSPCs along with wild-type cells into irradiated recipients

  • Tracking the contribution of modified cells to hematopoiesis using markers like CD45.1/CD45.2 or fluorescent reporters

  • Assessing competitive advantage/disadvantage upon secondary challenges (e.g., radiation)

• Non-competitive reconstitution:

  • Transplanting wild-type HSPCs into Thbd-deficient recipients or vice versa

  • Exposing reconstituted animals to radiation or other stressors

  • Evaluating hematopoietic recovery and survival

• In vitro colony formation assays:

  • Culturing HSPCs with varying levels of Thbd expression

  • Assessing colony-forming unit capacity in standard or stress conditions

  • Adding recombinant Thbd or aPC to culture medium to evaluate direct effects

These approaches have revealed that Thbd overexpression in HSPCs confers a selective advantage after radiation injury, with Thbd-overexpressing cells showing 1.5-fold enrichment in peripheral blood compared to vector-only controls. Conversely, Thbd-deficient HSPCs display reduced recovery after radiation exposure in competitive transplantation settings .

What methods can be used to assess the functional activity of recombinant mouse Thrombomodulin?

Several methods can be employed to assess the functional activity of recombinant mouse Thrombomodulin:

• Protein C activation assay:

  • Incubating recombinant Thbd with thrombin and protein C

  • Measuring the generation of activated protein C using chromogenic substrates

  • Quantifying activity based on the rate of substrate cleavage

• Thrombin binding assay:

  • Using surface plasmon resonance (SPR) to measure binding kinetics

  • Performing co-immunoprecipitation of Thbd with thrombin

  • Analyzing complex formation by gel filtration chromatography

• Cell-based assays:

  • Treating endothelial cells with recombinant Thbd

  • Measuring anti-inflammatory effects (e.g., reduction in NF-κB activation)

  • Assessing endothelial barrier function and cell survival

• In vivo functional assays:

  • Administering recombinant Thbd to wild-type or Thbd-deficient mice

  • Measuring systemic anticoagulant effects (clotting times, thrombin-antithrombin complexes)

  • Evaluating protection in disease models (e.g., radiation injury, stroke, sepsis)

When performing these assays, it is important to include appropriate controls, such as heat-inactivated Thbd or functionally inactive mutants, to confirm the specificity of observed effects .

What are the optimal storage and handling conditions for recombinant mouse Thrombomodulin?

Recombinant mouse Thrombomodulin requires specific storage and handling conditions to maintain its structural integrity and functional activity:

• Storage temperature: Store at -20°C or below for long-term stability. Some preparations may require storage at -80°C for optimal preservation.

• Solution conditions: Recombinant mouse Thbd is typically supplied in buffered solutions such as 20mM Tris, 150mM NaCl, pH 8.0. Avoid solutions with high concentrations of reducing agents that might disrupt disulfide bonds.

• Avoid freeze-thaw cycles: Minimize freeze-thaw cycles as they can lead to protein denaturation and loss of activity. Aliquot the protein solution before freezing to avoid repeated thawing of the entire stock.

• Working concentration: Dilute to working concentration in appropriate buffers immediately before use. PBS with 0.1% BSA can help prevent non-specific adsorption to tubes and loss of protein.

• Filtration: Use low protein-binding 0.2 μm filters if sterile filtration is required.

• Stability: When stored properly, recombinant mouse Thbd is typically stable for at least 6 months. Always validate the activity of the protein before use in critical experiments.

Proper handling is essential as Thbd contains multiple disulfide bonds and glycosylation sites that are crucial for its structural integrity and function .

What are the key considerations for designing experiments with Thrombomodulin-deficient mouse models?

When designing experiments with Thrombomodulin-deficient mouse models, several important considerations should be kept in mind:

• Choice of model:

  • Complete Thbd knockout mice are embryonic lethal, necessitating the use of conditional knockout models or hypomorphic variants.

  • Options include Thbd Pro/LacZ mice (with one functional Thbd allele encoding a variant with reduced ability to activate protein C) or tissue-specific conditional knockouts using the Cre-loxP system.

• Genetic background:

  • Consider the genetic background of the mice, as it can significantly influence experimental outcomes.

  • Use appropriate littermate controls that have undergone the same breeding strategy.

• Phenotypic characterization:

  • Thoroughly characterize the baseline phenotype before subjecting mice to experimental manipulations.

  • Assess coagulation parameters, vascular integrity, and relevant tissue-specific functions.

• Compensation mechanisms:

  • Be aware of potential compensatory mechanisms that may develop in response to Thbd deficiency.

  • Consider analyzing the expression of related molecules involved in coagulation and inflammation.

• Experimental design for transplantation studies:

  • For bone marrow transplantation experiments, consider both competitive and non-competitive approaches.

  • In competitive settings, use appropriate tracking markers (e.g., CD45.1/CD45.2) to distinguish donor-derived cells.

  • Allow sufficient time (typically 8 weeks) for complete hematopoietic reconstitution before subjecting animals to secondary challenges.

• Severity of Thbd deficiency:

  • Note that different models exhibit varying degrees of Thbd deficiency.

  • Thbd Pro/Pro mice show more severe deficiency than Thbd Pro mice, which impacts their sensitivity to experimental stressors like radiation.

These considerations are based on studies that have demonstrated increased radiation sensitivity in Thbd-deficient mice, with the LD50 dose shifted from ~8.75 Gy in wild-type mice to ~7.5 Gy in Thbd-deficient mice .

How can researchers troubleshoot issues with recombinant Thrombomodulin activity in experimental settings?

When encountering issues with recombinant Thrombomodulin activity in experimental settings, researchers can employ the following troubleshooting strategies:

• Verify protein integrity:

  • Perform SDS-PAGE under reducing and non-reducing conditions to assess protein degradation and disulfide bond formation.

  • Use Western blotting with domain-specific antibodies to confirm the presence of all functional domains.

  • Consider mass spectrometry analysis to evaluate post-translational modifications.

• Assess functional activity:

  • Conduct a protein C activation assay as a primary functional test.

  • Compare activity to a well-characterized reference standard.

  • Evaluate thrombin binding capacity if protein C activation is compromised.

• Optimize experimental conditions:

  • Test different buffer compositions, especially calcium concentration, which is crucial for Thbd-thrombin interaction.

  • Adjust pH conditions, as pH can significantly affect protein-protein interactions.

  • Consider the presence of potential inhibitors in the experimental system.

• Address species compatibility issues:

  • When using mouse Thbd with components from other species, verify cross-species compatibility.

  • Consider species-specific differences in interaction partners.

• Cell-based assay troubleshooting:

  • Ensure cells express appropriate receptors (e.g., EPCRs, PARs) for Thbd-mediated signaling.

  • Verify cell viability and responsiveness to positive controls.

  • Consider the timing of Thbd addition in relation to other experimental manipulations.

• In vivo experiment troubleshooting:

  • Optimize dosing regimen based on pharmacokinetic considerations.

  • Consider the route of administration (intravenous administration may be required for certain applications).

  • Evaluate the timing of administration relative to the experimental challenge.

By systematically addressing these potential issues, researchers can optimize the use of recombinant mouse Thbd in their experimental systems and ensure reliable and reproducible results .